(Q39676024)

English

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase

scientific article published on 25 July 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Sunny Guin

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Qi Ma

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Snehal Padhye

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yong-Qing Zhou

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hang-Ping Yao

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ming-Hai Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

publication date

25 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1073-1083

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The histological structure of some human lung cancers and the possible implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

The role of hypoxia-inducible factors in tumorigenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Regulation of angiogenesis by hypoxia and hypoxia-inducible factors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Hypoxia and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Drug resistance and the solid tumor microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Hypoxia and radiation therapy: past history, ongoing research, and future promise

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Identification of the ron gene product as the receptor for the human macrophage stimulating protein

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

RON, a tyrosine kinase receptor involved in tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Targeting tumour hypoxia in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Regulation of endocytosis via the oxygen-sensing pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Acute and chronic in vivo therapeutic resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Technology insight: cytotoxic drug immunoconjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Therapeutic nanoparticles for drug delivery in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1408-8

21 January 2018

Identifiers

10.1007/S00280-010-1408-8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39676024&oldid=2203078644"